Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas.

Arakawa Y, Saito R, Kanemura Y, Mishima K, Koriyama S, Narita Y, Kumabe T, Motomura K, Sugiyama K, Yamasaki F, Mukasa A, Kanamori M, Kuga D, Nagane M, Kakurai Y, Isobe K, Nakamura H.

Open source

DOI: 10.1093/neuonc/noaf258
Published: 2026-03-01
Container: Neuro Oncol
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/neuonc/noaf258,
  title = {Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas.},
  author = {Arakawa Y and  Saito R and  Kanemura Y and  Mishima K and  Koriyama S and  Narita Y and  Kumabe T and  Motomura K and  Sugiyama K and  Yamasaki F and  Mukasa A and  Kanamori M and  Kuga D and  Nagane M and  Kakurai Y and  Isobe K and  Nakamura H.},
  year = {2026},
  journal = {Neuro Oncol},
  doi = {10.1093/neuonc/noaf258},
  url = {https://doi.org/10.1093/neuonc/noaf258}
}

RIS

TY  - JOUR
TI  - Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas.
AU  - Arakawa Y
AU  -  Saito R
AU  -  Kanemura Y
AU  -  Mishima K
AU  -  Koriyama S
AU  -  Narita Y
AU  -  Kumabe T
AU  -  Motomura K
AU  -  Sugiyama K
AU  -  Yamasaki F
AU  -  Mukasa A
AU  -  Kanamori M
AU  -  Kuga D
AU  -  Nagane M
AU  -  Kakurai Y
AU  -  Isobe K
AU  -  Nakamura H.
PY  - 2026
JO  - Neuro Oncol
DO  - 10.1093/neuonc/noaf258
UR  - https://doi.org/10.1093/neuonc/noaf258
ER  -

APA

Y, A., R, S., Y, K., K, M., S, K., Y, N., T, K., K, M., K, S., F, Y., A, M., M, K., D, K., M, N., Y, K., K, I., & H., N. (2026). Phase II study of safusidenib erbumine in patients with chemotherapy- and radiotherapy-naïve isocitrate dehydrogenase 1-mutated WHO grade 2 gliomas.. Neuro Oncol. https://doi.org/10.1093/neuonc/noaf258

Source records

europe-pmc · retrieved 2026-09-25T16:44:29.134Z